Original Report: Patient-Oriented, Translational Research
Serum Bicarbonate and Structural and Functional Cardiac Abnormalities in Chronic Kidney Disease - A Report from the Chronic Renal Insufficiency Cohort StudyDobre M.a · Roy J.c · Tao K.c · Anderson A.H.c · Bansal N.e · Chen J.f · Deo R.d · Drawz P.g · Feldman H.I.c · Hamm L.L.f · Hostetter T.a · Kusek J.W.h · Lora C.i · Ojo A.O.j · Shrama K.k · Rahman M.a, b · the CRIC Study Investigators
aDivision of Nephrology and Hypertension, University Hospital Case Medical Center, Case Western Reserve University, and bLouis Stokes Cleveland VA Medical Center, Cleveland, Ohio., cCenter for Clinical Epidemiology and Biostatistics and dCardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa., eDivision of Nephrology, Kidney Research Institute, University of Washington, Seattle, Wash., fSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, New Orleans, La., gDivision of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, Minn., hNIDDK, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, iDepartment of Medicine, Division of Nephrology, University of Illinois at Chicago, Chicago, Ill., jDepartment of Medicine - Nephrology, University of Michigan, Ann Arbor, Mich., and kCenter for Renal Translational Medicine, Division of Nephrology-Hypertension, University of California at San Diego, San Diego, Calif., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Heart failure (HF) is a frequent occurrence in chronic kidney disease (CKD) patients and predicts poor survival. Serum bicarbonate is associated with increased rates of HF in CKD; however, the mechanisms leading to this association are incompletely understood. This study aims to assess whether serum bicarbonate is independently associated with structural and functional cardiac abnormalities in CKD. Methods: The association between serum bicarbonate and left ventricular (LV) hypertrophy (LVH), LV mass indexed to height2.7, LV geometry, ejection fraction (EF) and diastolic dysfunction was assessed in 3,483 participants without NYHA class III/IV HF, enrolled in the Chronic Renal Insufficiency Cohort study. Results: The mean estimated glomerular filtration rate was 42.5 ± 17 ml/min/1.73 m2. The overall prevalence of LVH was 51.2%, with 57.8, 50.9 and 47.7% for bicarbonate categories <22, 22-26 and >26 mmol/l, respectively. Participants with low bicarbonate were more likely to have LVH and abnormal LV geometry (OR 1.32; 95% CI 1.07-1.64, and OR 1.57; 95% CI 1.14-2.16, respectively). However, the association was not statistically significant after adjustment for demographics, traditional cardiovascular risk factors, medications and kidney function (OR 1.07; 95% CI 0.66-1.72, and OR 1.27; 95% CI 0.64-2.51, respectively). No association was found between bicarbonate and systolic or diastolic dysfunction. During follow-up, no significant changes in LV mass or EF were observed in any bicarbonate strata. Conclusions: In a large CKD study, serum bicarbonate was associated with LV mass and concentric LVH; however, this association was attenuated after adjustment for clinical factors suggesting that the observed cardiac effects are mediated through yet unknown mechanisms.
© 2016 Published by S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.